OrbiMed Capital GP VII LLC 4
4 · Passage BIO, Inc. · Filed Mar 3, 2020
Insider Transaction Report
Form 4
ORBIMED ADVISORS LLC
10% Owner
Transactions
- Conversion
Common Stock
2020-03-03+1,311,469→ 5,406,321 total(indirect: See Footnote) - Conversion
Series A-1 Preferred Stock
2020-03-03−3,721,552→ 0 total(indirect: See Footnote)→ Common Stock (3,721,552 underlying) - Conversion
Series B Preferred Stock
2020-03-03−541,002→ 0 total(indirect: See Footnote)→ Common Stock (541,002 underlying) - Conversion
Common Stock
2020-03-03+541,002→ 5,947,323 total(indirect: See Footnote) - Purchase
Common Stock
2020-02-28$18.00/sh+373,300$6,719,400→ 373,300 total(indirect: See Footnote) - Conversion
Series A-2 Preferred Stock
2020-03-03−1,311,469→ 0 total(indirect: See Footnote)→ Common Stock (1,311,469 underlying) - Conversion
Common Stock
2020-03-03+3,721,552→ 4,094,852 total(indirect: See Footnote)
Footnotes (2)
- [F1]The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP VII") is the general partner of OPI VII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP VII. OrbiMed GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI VII.
- [F2]Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering.